Have a personal or library account? Click to login
Renal Recovery in Critically Ill Adult Patients Treated With Veno-Venous or Veno-Arterial Extra Corporeal Membrane Oxygenation: A Retrospective Cohort Analysis Cover

Renal Recovery in Critically Ill Adult Patients Treated With Veno-Venous or Veno-Arterial Extra Corporeal Membrane Oxygenation: A Retrospective Cohort Analysis

Open Access
|May 2021

Figures & Tables

Fig.1

Trends in mean serum creatinine by type of ECMO support
Trends in mean serum creatinine by type of ECMO support

Fig. 2

Stages of acute kidney injury by type of ECMO support
Stages of acute kidney injury by type of ECMO support

Distribution of Acute Kidney Injury Risk Factors

FactorVA ECMOVV ECMOOdds Ratio of AKI (95% CI)p-value
IV contrast scan (%)37 (64%)33 (65%)0.96 (0.44, 2.11)0.92
Cardiopulmonary Bypass (%)14 (24%)1 (2%)15.9 (2.0, 125.9)0.0088
NSAID (%)9 (16%)15 (29%)0.44 (0.17, 1.12)0.085
Antibiotics (%)32 (55%)29 (57%)0.93 (0.44, 1.99)0.86
Sepsis (%)5 (9%)12 (24%)0.31 (0.10, 0.94)0.039
Hypotension (%)49 (84%)35 (69%)2.49 (0.99, 6.28)0.053
Vasopressor dependent Hypotension (%)38 (66%)31 (61%)1.23 (0.56, 2.68)0.61
CHF (%)14 (24%)10 (20%)1.31 (0.52, 3.26)0.57

Renal Outcomes by Type of ECMO Support

VA ECMOVV ECMOp-value
Complete Renal Recovery15 (26%)22 (43%)0.07
Partial Renal Recovery5 (9%)3 (6%)0.72
Dialysis Dependent1 (2%)1 (2%)>0.99
Death37 (64%)25 (49%)0.13

Primary Diagnosis of VA and VV ECMO groups

Primary DiagnosisVA ECMOVV ECMO
Acute Coronary Syndrome270
Congestive heart failure90
Sepsis512
Cardiac arrest50
Valvular heart disease40
Pulmonary embolism30
Cardiac arrhythmias30
Others815
Pneumonia010
Trauma010
Viral Pneumonia05
Drug Overdose03
Acute Pancreatitis02
Asthma01

Baseline Patient Characteristics by Type of ECMO Support

VA ECMOVV ECMOp-Value
Total Number6458
Age, mean (SD), years55.4 (15.8)42.9 (16.2)<0.0001
Male sex, n (%)50 (78%)40 (70%)0.21
White race, n (%)46 (79%)36 (71%)0.37
BMI, mean (SD)32.9 (9.0)30.4 (8.1)0.30
Smoking – No59 (92%)49 (84%)0.26
Diabetes mellitus, n (%)4 (6%)6 (10%)0.52
CAD, n (%)14 (22%)4 (7%)0.023
HTN, n (%)16 (25%)15 (26%)>0.99
CKD, n (%)10 (16%)3 (5%)0.080
Hyperlipidaemia, n (%)14 (22%)5 (9%)0.049
COPD, n (%)7 (11%)6 (10%)>0.99
APACHE II, mean (SD)24.8 (7.9)28.0 (6.2)0.014
Charlson Comorbidity Index, mean (SD)2.4 (2.7)1.8 (3.0)0.27
Lactic acid, mean (SD), mmol/L7.4 (4.4)4.4 (3.2)0.0002
ICU length of stay, mean (SD), days11.6 (10.8)24.5 (15.4)<0.0001
AKI, all stage, n (%)58 (91%)51 (88%)0.77
DOI: https://doi.org/10.2478/jccm-2021-0006 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Language: English
Page range: 104 - 112
Submitted on: Oct 8, 2020
Accepted on: Jan 27, 2021
Published on: May 12, 2021
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2021 Braghadheeswar Thyagarajan, Mariana Murea, Deanna N. Jones, Amit K. Saha, Gregory B. Russell, Ashish K. Khanna, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.